With expansion a prime focus for businesses worldwide, many are looking towards rapidly establishing new regions of growth, particularly in Asia, Pacifi c Rim countries.
The latest business developments from across Asia by Heather Hobbs To appear in our next issue, send your Business and Financial News stories to
heather@intlabmate.com
This section of International Labmate will especially look at the success of both Asian and European companies with established premises or business partnerships, highlighting the opportunities that exist while realising potential for other companies to move into export markets.
Acquisition Enhances Group’s Position in China’s Research Market
Patrick Bennett, Group CEO of SPT Labtech, said: “We are delighted to complete the deal and we are very excited to bring LBD into the group. This investment highlights SPT Life Sciences’ commitment to developing a global portfolio of companies with a range of specialisms that help life science professionals world-wide to achieve their research goals. For over 10 years the team at LBD have supported the growing life science research community in China and we believe that this investment will ensure they are able to do so going forward.”
Patrick Bennett Sean Xiao
Global technology support group SPT Life Sciences, specialising in liquid handling, sample management and cryoEM, has completed its acquisition of LBD Life Sciences, a leading supplier of instrumentation to the drug discovery market in China.
SPT Life Sciences, which received backing from investment fi rm Battery Ventures, already held a minority stake in the Shanghai company and the acquisition will extend its reach into the growing Chinese life sciences research market. LBD Life Sciences will join the family of companies including SPT Labtech Ltd and Quantifoil.
Sean Xiao, Managing Director of LBD Life Sciences commented: “As part of SPT Life Sciences we will remain deeply committed to solving Asia’s life science customers’ toughest research problems by leveraging our expertise, and enabling access to cutting edge instrumentation. We can see many advantages of being part of the group and look forward to the future.”
More information online:
ilmt.co/PL/DKgW 53273pr@reply-direct.com
Collaboration Extends
Development Programme Targets
An expansion to its existing multi-target collaboration agreement with LG Chem, the life sciences division of the South Korean LG Group, will see Avacta’s Affi mer XT™ serum half-life extension system incorporated into a new programme of biotherapeutics development that could potentially bring milestone payments of up to $55 million to Avacta Group.
The extension of the partnership, original established in December 2018, includes an undisclosed additional upfront payment, plus near-term pre-clinical milestones and longer- term clinical development milestones totalling $98.5 million for two therapeutics to be developed using the Affi mer XT technology. LG Chem also has the exclusive rights to develop and commercialise these new products on a world-wide basis.
Centre Increases Process Development Opportunities in Shanghai
Science and technology company Merck has opened its M Lab™ Collaboration Center in Shanghai, the company’s largest of nine centres worldwide.
“With the booming pharmaceutical industry in Asia and greater emphasis on novel drug therapies, we see an increase in R&D on leading-edge treatments including cell and gene therapies in China,” said Udit Batra, member of the Merck Executive Board and CEO, Life Science. “Our M Lab™ Collaboration Centre offers customisable solutions and services that help bio pharmaceutical and biologics companies improve their processes from drug discovery, development to manufacturing - saving costs and increasing speed to market.”
With a total lab size of approximately 10,000m2, Merck’s newest collaboration Centre is located in Pudong, at the heart of the biomedical sciences and research community. It includes pilot scale and process development support labs that offer non-GMP (Good Manufacturing Practice) lab space where pharmaceutical and biopharmaceutical manufacturers can explore ideas, learn innovative techniques and work side-by-side with the company’s scientists and engineers to solve critical process development and production challenges.
52859pr@reply-direct.com
Avacta Group chief executive Dr Alastair Smith (pictured) said: “I am delighted with this expansion to the agreement with LG Chem, with whom we have developed a strong collaborative partnership. LG Chem is a world-class drug development partner with excellent biologics manufacturing and clinical development capabilities and a pioneering vision to develop innovative therapies.”
53332pr@reply-direct.com
RedShiftBio Appoints Topbiox as Exclusive
Distributor in China RedShift BioAnalytics, Inc announces its award winning AQS3™pro, based on Microfl uidic Modulation Spectroscopy (MMS) technology, is now available in China, following the appointment of Beijing-based Topbiox as exclusive distributor. Designed specifi cally for protein characterisation applications in the biopharmaceutical industry, the technology has already seen wide adoption in the analytical toolkit of companies developing life-saving biotherapeutics and vaccines.
Partnership to Advance Liver Fibrosis Teatments
Biotech Engitix and Japanese multinational Takeda Pharmaceutical are working jointly on the confi rmation and validation of targets leading to preclinical development of therapeutics in advanced liver fi brosis, using the transatlantic biotech’s extracellular matrix (ECM) discovery platform.
Under the terms of the deal, Takeda will have exclusive rights to develop and commercialise clinical candidates, including those for non-alcoholic steatohepatitis (NASH), generated against validated targets derived from the collaboration.
Engitix receives an upfront payment, with additional near-term payments as work on selected targets develops; it also stands to bank more than $500 million for the achievement of preclinical, development, regulatory and commercial milestones, as well as further royalty payments generated by sales.
“Having Takeda, one of the world’s leading pharmaceutical companies with world-class drug development and commercialisation capabilities, as a major collaborator, will accelerate the translation of novel ECM-derived targets into potential therapeutics for humans,” said Dr Giuseppe Mazza, the UK group’s co-founder and Chief Executive.
“We are excited to continue working with Takeda as this is the only partnership in the fi eld of liver fi brosis currently using a human disease-specifi c ECM platform, paving the way for potential fi rst-in class anti-fi brotic therapeutics.”
53331pr@reply-direct.com
“Topbiox is an experienced distributor of biophysical characterisation tools in China. Its reputation for providing the highest quality instrumentation, service and applications support to its customers make it a perfect partner to us,” said Julien Bradley, CEO RedShiftBio.
The partnership means that Chinese scientists can now experience demonstrations and run samples onsite. Topbiox will be responsible for all sales, marketing, service and support.
52753pr@reply-direct.com
Does your company sell or wish to sell laboratory products and services to the economies of Asia? Are you looking for local distributors and agents to represent you?
If so, why not advertise your products in our market-leading journal Lab Asia.
Email:
info@intlabmate.com
Business
Opportunities Asia
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76
